Form 4 for DNA Ginkgo Bioworks Holdings, Inc.
Accepted 2024-05-14 00:00:00 ET · period of report 2024-05-14 · accession 0001127602-24-015293 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-14 | 2024-05-14 | DNA | DEKKERS MARIJN E | Dir | S - Sale | $0.93 | -1.73M | 281.2K | -86% | -$1.61M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-05-14 | S | D | 1,727,056 | $0.93 | 281,217 | D | — | — | (F1) Includes 281,217 earn-out shares that will vest in substantially equal installments if the Issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $15.00, $17.50 and $20.00. |